146 related articles for article (PubMed ID: 22068354)
1. Rapid infusion with rituximab: short term safety in systemic autoimmune diseases.
Larsen JL; Jacobsen S
Rheumatol Int; 2013 Feb; 33(2):529-33. PubMed ID: 22068354
[TBL] [Abstract][Full Text] [Related]
2. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
[TBL] [Abstract][Full Text] [Related]
3. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.
Pritchard CH; Greenwald MW; Kremer JM; Gaylis NB; Rigby W; Zlotnick S; Chung C; Jaber B; Reiss W;
BMC Musculoskelet Disord; 2014 May; 15():177. PubMed ID: 24884454
[TBL] [Abstract][Full Text] [Related]
4. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Brown BA; Torabi M
Drug Saf; 2011 Feb; 34(2):117-23. PubMed ID: 21247220
[TBL] [Abstract][Full Text] [Related]
5. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
6. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
Tony HP; Burmester G; Schulze-Koops H; Grunke M; Henes J; Kötter I; Haas J; Unger L; Lovric S; Haubitz M; Fischer-Betz R; Chehab G; Rubbert-Roth A; Specker C; Weinerth J; Holle J; Müller-Ladner U; König R; Fiehn C; Burgwinkel P; Budde K; Sörensen H; Meurer M; Aringer M; Kieseier B; Erfurt-Berge C; Sticherling M; Veelken R; Ziemann U; Strutz F; von Wussow P; Meier FM; Hunzelmann N; Schmidt E; Bergner R; Schwarting A; Eming R; Hertl M; Stadler R; Schwarz-Eywill M; Wassenberg S; Fleck M; Metzler C; Zettl U; Westphal J; Heitmann S; Herzog AL; Wiendl H; Jakob W; Schmidt E; Freivogel K; Dörner T;
Arthritis Res Ther; 2011 May; 13(3):R75. PubMed ID: 21569519
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
8. Myocardial infarction after rituximab treatment for rheumatoid arthritis: Is there a link?
van Sijl AM; van der Weele W; Nurmohamed MT
Curr Pharm Des; 2014; 20(4):496-9. PubMed ID: 23565629
[TBL] [Abstract][Full Text] [Related]
9. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
10. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
Dale RC; Brilot F; Duffy LV; Twilt M; Waldman AT; Narula S; Muscal E; Deiva K; Andersen E; Eyre MR; Eleftheriou D; Brogan PA; Kneen R; Alper G; Anlar B; Wassmer E; Heineman K; Hemingway C; Riney CJ; Kornberg A; Tardieu M; Stocco A; Banwell B; Gorman MP; Benseler SM; Lim M
Neurology; 2014 Jul; 83(2):142-50. PubMed ID: 24920861
[TBL] [Abstract][Full Text] [Related]
11. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
[TBL] [Abstract][Full Text] [Related]
12. Immediate infusional reactions to intravenous immunobiological agents for the treatment of autoimmune diseases: experience of 2126 procedures in a non-oncologic infusion centre.
Moss IB; Moss MB; dos Reis DS; Coelho RM
Rev Bras Reumatol; 2014; 54(2):102-9. PubMed ID: 24878856
[TBL] [Abstract][Full Text] [Related]
13. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
[TBL] [Abstract][Full Text] [Related]
14. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
15. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.
Emery P; Mease PJ; Rubbert-Roth A; Curtis JR; Müller-Ladner U; Gaylis NB; Williams S; Reynard M; Tyrrell H
Rheumatology (Oxford); 2011 Dec; 50(12):2223-32. PubMed ID: 21926153
[TBL] [Abstract][Full Text] [Related]
16. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
Fleischmann RM
Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the safety and feasibility of rapid rituximab infusion.
Lang D; Prouse J; Barry F; Catherwood A; Chaplin K; Elliott L; Greco K; McGahey W; Nilsen J; Singhal N
Asia Pac J Clin Oncol; 2012 Mar; 8(1):71-5. PubMed ID: 22369446
[TBL] [Abstract][Full Text] [Related]
18. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.
Jung JW; Kang HR; Lee SH; Cho SH
Oncology; 2014; 86(3):127-34. PubMed ID: 24480856
[TBL] [Abstract][Full Text] [Related]
19. Safety of rituximab in rheumatoid arthritis.
Covelli M; Sarzi-Puttini P; Atzeni F; Macchioni P
Reumatismo; 2010; 62(2):101-6. PubMed ID: 20657886
[TBL] [Abstract][Full Text] [Related]
20. A safety analysis of oral prednisone as a pretreatment for rituximab in rheumatoid arthritis.
Carter JD; Zarabadi SA; Ricca LR; McNeil A; Valeriano-Marcet J; Vasey FB; Sebba AI
Clin Rheumatol; 2012 Nov; 31(11):1605-10. PubMed ID: 22923178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
